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NON-CYCLING haemopoietic stem cells
appear to be resistant to the toxic effects
of bleomycin (BLM) (Twentyman &
Bleehen, 1973; Briganti et al., 1975) the
well known anticancer antibiotic which in
experimental research (Matsuda et al.,
1968; Boggs et al., 1974) and in clinical
practice (Ichikawa et al., 1970; Mosher
et al., 1972; Umezawa, 1976) avoids major
marrow toxicity. Proliferating stem cells
are however more sensitive to the toxic
action ofthe drug (Twentyman & Bleehen,
1973; Briganti et al., 1975). It is therefore
possible that if tile drug is given in frac-
tionated doses, the quantitative and pro-
liferative changes in the stem-cell popula-
tion caused bv the first doses, although
slight, might modify the susceptibility of
the population to the follow-ing doses of
the drug. In fact relatively large doses of
BLM, given once daily for 3 days to normal
mice, caused a small but persistent reduc-
tion of the marrow's ability to produce
spleen colonies (Boggs et al., 1974). The
present study has been undertaken to
investigate the effects on mouse marrow
stem cells of prolonged (over many weeks)
administration of BLM in much smaller
daily doses, extrapolated from those used
in clinical practice by an appropriate con-
version factor (Freireich et al., 1966).
Significant haematological parameters and
marrowv CFU-S content were determined
at preset intervals, according to an experi-
mental model already applied to other
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anticancer drugs (Pannacciulli et al.,
1977a, b).
(C57BL/C3H)Fl mice of both sexes,
2-3 months old at the beginning of the
experiment, received bleomycin (Roger-
Bellon) dissolved in saline by daily i.p.
injection, 5 days a week for 16 weeks. The
daily dose ranged from 5-67 + 0-22 mg/kg
body wt at thebeginningoftheexperiment
to 5-46 + 0K13 mg/kg at the end. These
doses were extrapolated from the dose
of 30 mg twice weekly used in man by the
conversion factor ofFreireich et al. (1966).
At the end of weeks 1, 2, 3, 4, 6, 8, 10,
12, 14 and 16 during the period of drug
administration, 5 treated mice, randomly
chosen from different cages, and 5 matched
controls daily injected with saline were
killed. The femoral content of their stem
cells was determined, along with spleen
weight, absolute number of nucleated
marrow%N cells in the femur, volume of
packed red blood cells (PRCV), total
leucocyte count and the number of
reticulocytes per 100 red cells in orbital-
sinus blood. The peripheral-blood counts
were by conventional methods. Differential
counts on peripheral blood or marrow
cells were not made. The femur CFU-S
content was assayed according to the Till
& McCulloch transplant method (1961).
Radiation of host mice was carried out
with a Theratron Junior, operated at
1700 Ci. The total dose delivered to the
mice was 900 rad. A total of 0 5 ml ofG. V. BOGLIOLO ET AL.
200
A
150
100
50
B
10
To 2 4 6 8 10 12 14 16
weeks
Fie. Changes in )eriplleral-blood -white cells
(A) andi marirow CFU-S (B) (hurinig chroniC
a(lministration of BL\I to C57BL/C3H
FF1 mice. Observedl values are reported as
per(ent of nor mal controls.
femnoral cell suispension in mediunm diluted
to contain 4 x 104 cells was injected into
tail vessels. The number of visible colonies
was counted in spleen excised from the
host mice killed in ether 9 days after
injection. The fraction ofsurviving CFU-S
per femur is expressed as a percentage of
control values obtained from correspond-
ing groups of untreated mice. Student's
t test was used to assess differences
between treated mice and control means.
The mortality rate and the body-weight
increment curves of treated animals
matched those of untreated ones. PRCV
did not vary significantly from that of
controls (Table). Significant but transitory
decreases both of WBC and reticulocyte
level in peripheral blood and of marrow
cellularity were observed at different times
during the drug administration. On the
whole the haematological pattern appears
only mildly affected.
The femoral CFU-S content drops to
16% of controls 2 weeks after the begin-
ning of the drug administration (Fig. &
Table). It remains at levels lower than50%/
of controls through the following 10-week
study period. After the 8th week of the
experiment the CFU-S content increases
slowly, to return to the normal level at the
en(1 of the experiment.
During prolonged administration tomice
of small doses of BLM there is a marked
difference between the behaviour of pluri-
potent stem cells and of recognizable
haemopoietic precursors. The marrow
CFU-S content appears severely reduced
in the first weeks of treatment, and starts
to recover only during the second half of
observation period. On the contrary, the
haematological pattern remains substan-
TABLE. Hazenatological data (means + s.e.) in mice treate(d uwith BLM
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44 + 1
4:+ 1
41 + 1
45+ 1
46+ 1
45+1
44+:3
42+ 1
40(+ 1
:39+ 1
40(+2
\VABCI
(10'11)
50+2
27+3
25 + 3
42+ 1
30+ :3
56+4
45+5
44+6
29 + 3
45+7
51 + 6
Retias
27+2
27+2
17+4
16 + 2
:30+ I
:16+ 2
5+ 1
16+4
19+1
2:3 + 2
26+ 2
Spleen
wt
(mg)
28+2
69+5
85+ 10
71 + 6
95+5
95 + 9
82 + 7
106+3
86 + 7
80+6
1(1 + 9
Cells
pell
femur
( x 1(0-6)*
13-84
1()02-0:(
7.75
13 30
8-67
14 91
11-00
1233
12 50
7:33
11-83
Tlotal
CEU-S
per
f-tmur
:3934 + 92
2932 -4 93t
(625-X 98t
113304 94t
585 + 45t
1939+ 119t
1301 * ]I1 t
1541 + 93t
1687 + 102t
2437± 120t
4223± 1201
* The bonie, marrows of(lonon mice have beein poole(l and cell c(UoItS
macle on the pool.
t Significanit (21' < 0.05) compared wvith inormal mice.
I Not significarit (21' > 0.05) Compared wvith inor-mal mnice.
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tially normal. By the nadir of stem cell
depletion (2 weeks) the mice had received
a cumulative dose of about 60 mg/kg of
the drtug. If given in a single dose this
amount, would leave the CFU-S content!
almost intact in resting marrow, but would
reduce it to below 400o of control in
regenerating marrow (Twentyman & Blee-
hen, 1973). This may explain why the
same amount of proliferation-dependent
BLM given in repeated doses would result
in a depletion similar to the above, con-
sidering that at each dose the kinetics of
the haemopoietic population have been
altered by the previous doses.
The severe depletion of marrowT CFU-S
induced by repeated small doses of BLM
may be the result of a direct action of the
cytotoxic druig on the stem cells (destruc-
tion, hampered differentiation, prolonged
generation time) plus the indirect con-
sequence of the compensatory effort of
haemopoiesis (enhanced removal of pluri-
potent stem cells due to differentiation to
committed precursor cells and migration
to other haemopoietic sites).
The recovery of (CFU-S takes place in
spite of the continued administration of
the drug. Even in clinical observations of
marrow suppression there was recovery to
pretreatment, counts, in spite of continued
BLM administration (Krakoff & Yagoda,
1973). It is possible that in the long run
the inactivation of the drug, already par-
ticularly effective in marrow (Umezawa,
1976) becomes progressively more efficient.
Alternatively the adaptation ofthe haemo-
poietic system may further evolve to reach
a new steady state based on a different
dynamic equilibrium.
The pattern seen during chronic admin-
istration of BLM seems comparable with
that found in rats under continuous
irradiation (45-50 rad/day) when a tnormal
red-cell production is associated with a
severely depleted stem-cell population
(Lamerton, 1966; Blackett, 1967). This
was explained by increased proliferation in
the committed precursor stages. More
recently, however, Knospe et al. (I1977)
found in rnice that myeloid progenitor
cells (CFU-C) exhibited a response to
continuous irradiation similar to that of
CFU-S.
In comparison with other cy=cle-specific
(Irugs similarly administered to mice for
manv weeks in low doses (Pannacciulli
et al. 1977a, b) BLM induces changes in
CFU which are similar t,o those induced by
methotrexate, but different, from those
induced by azathioprine, cyclophospha-
mide, hydroxyurea, vinblastine or Vinl-
cristine. It is obvious that, cycle-specificity
alone cannot explain these differences.
Depletion of the pluripotent stem-cell
)opulation, induced by BLM administered
in repeated small doses must be taken into
account in the drug's clinical applicationi.
In mice this action is not, associated with
a comparable effect oni differentiat,ed
haenmopoietic cells. If the same wtere true
in humans, the uisual indices of marrow
toxicity (i.e. AVBBC1 level anid marrow cellu-
larity) coul(l not be used for the evaltuation
of the truie impact of BLM on marrow
function.
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